Ebola Successfully Neutralized By Latest Generation Polyclonal Immunotherapy

Ebola Successfully Neutralized By Latest Generation Polyclonal Immunotherapy

August 15, 2018
USD Discovery District Announces Anchor Tenants For Innovation Community

USD Discovery District Announces Anchor Tenants For Innovation Community

June 4, 2018
SAB Biotherapeutics Expands VAC Team

SAB Biotherapeutics Expands VAC Team

May 15, 2018
SAB Capra Awarded $225K From NIH To Broaden Novel Immunotherapy Platform

SAB Capra Awarded $225K From NIH To Broaden Novel Immunotherapy Platform

February 1, 2018
First Treatment For MERS Appears Safe In NIH Phase I Clinical Trial

First Treatment For MERS Appears Safe In NIH Phase I Clinical Trial

January 10, 2018
First-In-Human Trial Of New Immunotherapy Approach Shows Efficacy In Antibiotic Resistance

First-In-Human Trial Of New Immunotherapy Approach Shows Efficacy In Antibiotic Resistance

December 21, 2017
SAB Biotherapeutics Launches Utah-Based Subsidiary SAB Capra, LLC.

SAB Biotherapeutics Launches Utah-Based Subsidiary SAB Capra, LLC.

December 20, 2017
SAB Biotherapeutics’ Pharm Groundbreaking Highlights Broad Impact

SAB Biotherapeutics’ Pharm Groundbreaking Highlights Broad Impact

October 5, 2017
SAB Biotherapeutics Integrates Operations With New Production Facility

SAB Biotherapeutics Integrates Operations With New Production Facility

August 30, 2017
Pharmaceutical Entrepreneur, William J. Polvino, M.D. Joins SAB Biotherapeutics’ Business Advisory Board

Pharmaceutical Entrepreneur, William J. Polvino, M.D. Joins SAB Biotherapeutics’ Business Advisory Board

August 3, 2017
SAB Biotherapeutics Strengthens Board Of Directors With Appointment Of Biotech Veteran

SAB Biotherapeutics Strengthens Board Of Directors With Appointment Of Biotech Veteran

April 26, 2017
SAB Biotherapeutics Names Christoph Bausch As Chief Science Officer

SAB Biotherapeutics Names Christoph Bausch As Chief Science Officer

April 25, 2017